Early lenalidomide (LEN) dose intensity and durable RBC-transfusion independence (RBC-TI) in patients (pts) with low-/int-1-risk myelodysplastic syndromes (MDS) and del5q.
A. F. List
Consultant or Advisory Role - Celgene
Honoraria - Celgene
Research Funding - Celgene
A. Giagounidis
Consultant or Advisory Role - Celgene
Honoraria - Celgene
J. T. Backstrom
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
T. Fu
Employment or Leadership Position - Celgene
Stock Ownership - Celgene
P. Fenaux
Honoraria - Celgene
Research Funding - Celgene